The National Academy of Medicine has elected 100 new members, including Merit Cudkowicz, MD, MSc, Chief of Neurology and Director of the Healey Center for ALS at Mass General. Dr. Cudkowicz was selected for leading the first neuroscience antisense oligonucleotide therapy trial, establishing the first platform trial in amyotrophic lateral sclerosis (ALS), helping to develop a successful treatment for sporadic ALS, AMX0035, and creating global networks to accelerate treatment development for many disorders.

Learn more about the newly inducted members at NAM.edu.

  • Merit Cudkowicz, MD

    • Chief, Neurology Department
    • Director, Sean M. Healey & AMG Center for ALS
    • Director, Neurological Clinical Research Institute

Type

Centers and Departments

Topics

HEALEY ALS Platform Trial

Find out about the innovative new HEALEY ALS Platform Trial, which is accelerating efforts to bring new ALS treatments to patients.

Learn more